Community assessment of the predictability of cancer protein and phosphoprotein levels from genomics and transcriptomics.

  • Multiomics Data Science
  • Quantitative Biology Unit
August 26, 2020 By:
  • Yang M
  • Petralia F
  • Li Z
  • Li H
  • Ma W
  • Song X
  • Kim S
  • Lee H
  • Yu H
  • Lee B
  • Bae S
  • Heo E
  • Kaczmarczyk J
  • Stępniak P
  • Warchoł M
  • Yu T
  • Calinawan AP
  • Boutros PC
  • Payne SH
  • Reva B
  • NCI-CPTAC-DREAM Consortium (Azuaje F. KT
  • Kim S.
  • Muller A.
  • Nazarov P.
  • Tranchevent L. as collaborators)
  • Boja E
  • Rodriguez H
  • Stolovitzky G
  • Guan Y
  • Kang J
  • Wang P
  • Fenyö D
  • Saez-Rodriguez J.

Cancer is driven by genomic alterations, but the processes causing this disease are largely performed by proteins. However, proteins are harder and more expensive to measure than genes and transcripts. To catalyze developments of methods to infer protein levels from other omics measurements, we leveraged crowdsourcing via the NCI-CPTAC DREAM proteogenomic challenge. We asked for methods to predict protein and phosphorylation levels from genomic and transcriptomic data in cancer patients. The best performance was achieved by an ensemble of models, including as predictors transcript level of the corresponding genes, interaction between genes, conservation across tumor types, and phosphosite proximity for phosphorylation prediction. Proteins from metabolic pathways and complexes were the best and worst predicted, respectively. The performance of even the best-performing model was modest, suggesting that many proteins are strongly regulated through translational control and degradation. Our results set a reference for the limitations of computational inference in proteogenomics. A record of this paper's transparent peer review process is included in the Supplemental Information.

2020 Aug. Cell Syst.11(2):186-195 e9. Epub 2020 Jul 24.
Other information